|
Enhancing T Cell Therapy of Cancer
|
4P01CA094237-14
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
2R01CA116548-11A1
|
$249,637
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$8,261
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$11,963
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$8,321
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$34,996
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S5
|
$134,220
|
$9,395
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-10
|
$3,253,119
|
$227,718
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-03
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-04S1
|
$13,734
|
$13,734
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
4R01CA166749-04
|
$318,913
|
$318,913
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-03S1
|
$3,025,319
|
$242,026
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-03
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-03
|
$21,084,883
|
$1,686,791
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Structural Variation in Neuroblastoma
|
1R01CA204974-01A1
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Altered mitochondria-ER signaling as a cause of chemotherapy resistance
|
1R21CA198430-01A1
|
$193,314
|
$193,314
|
HOGARTY, MICHAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
4R01CA124709-09
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-02
|
$606,838
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Preclinical Testing Consortium
|
5U01CA199287-02
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-08
|
$374,344
|
$374,344
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblastoma
|
1K08CA194162-01A1
|
$168,264
|
$168,264
|
SCHNEPP, ROBERT
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exploring the oncogenic potential of human APOBEC3 cytosine deaminases
|
5R21CA185799-02
|
$219,240
|
$74,542
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-03
|
$665,155
|
$665,155
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
2T32CA009659-21A1
|
$64,768
|
$32,384
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
4R01CA129377-09
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
4U01CA168426-05
|
$1,238,106
|
$1,238,106
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S1
|
$120,000
|
$4,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S2
|
$60,000
|
$2,400
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S3
|
$121,873
|
$4,875
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S4
|
$150,866
|
$6,035
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S5
|
$199,541
|
$7,982
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S6
|
$500,000
|
$20,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-42
|
$3,792,720
|
$151,709
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-02
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-05
|
$363,426
|
$363,426
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
1R01CA197336-01A1
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Epigenetic Regulation of Neuroblast Differentiation
|
5F31CA192558-02
|
$34,000
|
$34,000
|
GAVIGLIO, ANGELA
|
DUKE UNIVERSITY
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
4R01CA123490-09
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-25
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-02
|
$351,644
|
$175,822
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Prenatal stress and neuroblastoma development - is there a link?
|
5R21CA198698-02
|
$169,106
|
$169,106
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
3P30CA051008-23S1
|
$350,000
|
$10,500
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Georgetown University Lombardi Cancer Center Support Grant
|
5P30CA051008-23
|
$2,306,055
|
$69,182
|
WEINER, LOUIS
|
GEORGETOWN UNIVERSITY
|
|
Targeting nutrient-sensing pathways in cancer
|
1K22CA201103-01
|
$190,640
|
$190,640
|
LAZARUS, MICHAEL
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
5R21CA181417-02
|
$219,957
|
$109,979
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
|
Large-scale Genetic Analyses of Human Cancer
|
4R01CA121113-10
|
$279,212
|
$13,961
|
VELCULESCU, VICTOR
|
JOHNS HOPKINS UNIVERSITY
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
5R00CA178189-04
|
$249,000
|
$249,000
|
ZHU, SHIZHEN
|
MAYO CLINIC ROCHESTER
|
|
Research Management and Support
|
RMS ES 2016
|
$320,501,735
|
$101,000
|
N/A
|
National Institutes of Health
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,340,699
|
$167,035
|
Glod, John
|
CCR (NCI)
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$817,629
|
$817,629
|
Ho, Mitchell
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $19,959,764
|